← Eichor
Condition: Treatment Of Recurrent Ovarian Cancer Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Treatment Of Recurrent Ovarian Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Phase 3 · 106 location(s) · Verastem, Inc. · NCT06072781Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells
Phase 1 · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT06305299Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Tre
Phase 3 · 16 location(s) · Genmab · NCT07225270HS-10502 Combination Treatment in Patients With Advanced Solid Tumors
Phase 1 · 1 location(s) · Jiangsu Hansoh Pharmaceutical Co., Ltd. · NCT06769425Evaluation of 68Ga-FAPI-46 and 18F-FDG PET/CT Imaging for Detecting Recurrent Tumor Lesions in Patients of Ovarian Cance
NA · 1 location(s) · Chang Gung Memorial Hospital · NCT06232122Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Beva
Phase 3 · 32 location(s) · Genelux Corporation · NCT05281471Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Can
EARLY_Phase 1 · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT07144826Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
Phase 1 · 2 location(s) · M.D. Anderson Cancer Center · NCT03968406Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study
Phase N/A · 1 location(s) · University of Washington · NCT06295965Application of MRD Combined With Personalized Vaccine in the Treatment of Postoperative Recurrence Prevention of EOC
Phase 2/Phase 3 · 1 location(s) · Second Affiliated Hospital of Wenzhou Medical University · NCT06341907A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combinatio
Phase 1 · 5 location(s) · Regeneron Pharmaceuticals · NCT06469281Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07480954RC48 in Combination With AK104 and Bevacizumab in OCCC
Phase 2 · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT06540729Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
Phase 1 · 2 location(s) · Dana-Farber Cancer Institute · NCT06321484A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.
Phase 2 · 17 location(s) · Shanghai Jiaolian Drug Research and Development Co., Ltd · NCT06434610A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants Wit
Phase 2 · 40 location(s) · AbbVie · NCT06365853Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer.
Phase 2 · 1 location(s) · Fujian Cancer Hospital · NCT05753826Study of Fully Human B7H3 CAR-T in Treating Recurrent Malignant Ovarian Cancer
Phase 1/Phase 2 · 1 location(s) · The Affiliated Hospital of Xuzhou Medical University · NCT05211557Bespoke ctDNA Assay for Recurrence and Treatment Response Monitoring in Advanced Epithelial Ovarian Cancer
Phase N/A · 1 location(s) · Fudan University · NCT05446545A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks
Phase N/A · 1 location(s) · Fondazione del Piemonte per l'Oncologia · NCT07469709CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT05410717Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer
NA · 1 location(s) · Shanghai Gynecologic Oncology Group · NCT05236686Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Re
Phase 2 · 2 location(s) · Roswell Park Cancer Institute · NCT05231122Feasibility of CALM in Patients With Ovarian Cancer
NA · 1 location(s) · University Health Network, Toronto · NCT06459271Salvage Systemic Therapy With or Without Stereotactic Ablative Radiotherapy for Recurrent Ovarian Cancer
NA · 1 location(s) · Yonsei University · NCT05444270A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer
Phase 1 · 4 location(s) · Outpace Bio, Inc. · NCT07030907Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade En
Phase 2 · 1 location(s) · University College, London · NCT05080556A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer
Phase 1/Phase 2 · 28 location(s) · Compugen Ltd · NCT06888921MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
Phase 1 · 1 location(s) · Mayo Clinic · NCT06483048Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy
Phase 2 · 1 location(s) · Yonsei University · NCT07340164
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.